Regeneron

Balance sheet (2026-06-30): cash + equivalents $2,455.8M, current marketable securities $5,538.8M (≈$8.0B combined), stockholders' equity $31,711.4M. GAAP diluted EPS Q2 2026 ~$12.01 (+11% YoY).

• technical_scarcity: 7/10 — The scarcity is the approved-product + indication-stack + safety-database barrier: Dupixent spans 6+ indications with no interchangeable competitor, and EYLEA HD's longer-dosing formulation is still protected. But the platform itself is replicable in principle (multiple transgenic-mouse antibody platforms exist), and biosimilars (Amgen, Samsung Bioepis, Biocon) are already eroding the 2 mg EYLEA leg (−45% YoY). Scarcity is high on the approved franchise, moderate on the platform.

• economic_capture: 8/10 — 30.1% GAAP operating margin on $4.29B quarterly revenue, ~34% profit-share capture on Dupixent's $6.0B quarterly global sales, and ~$8.0B cash. Cash generation is strong even with a 38% R&D intensity. The one capture headwind: net income −7% YoY because the EYLEA 2 mg LoE + R&D ramp are absorbing the Dupixent upside.

• time_to_monetize: 8/10 — Monetization is already in the P&L: Dupixent +38%, Libtayo +30% (all-time high $489M), EYLEA HD +52%. Near-term catalysts are the EYLEA HD ramp and Lynozyfic/Ordspono launch curves; the terminal risk is Dupixent's own LoE (~2031 US) which the pipeline must backfill.

Composite ≈ 7.7/10. Consensus gap is computed separately by the automated pipeline — not scored here.

• monetization model: Product sales of proprietary biologics; collaboration revenue/profit-share/reimbursements from Sanofi and Bayer; other/licensing. (REGN 10-K FY2024, Business & Rev Rec notes, acc. 0000872589-25-000010, sec.gov )
• revenue mix: One reportable segment. FY2024 total revenue ~$14.20B: EYLEA/EYLEA HD ~43%; Sanofi/Bayer collaboration ~38%; other product sales ~16%; other revenue ~3%. (same 10-K, segment/revenue disaggregation note)
• who pays: Payers & Insurers/PBMs/government programs; Health Systems & Providers; patients; Pharma & Biotech (Sanofi/Bayer); distributors/specialty pharmacies as channel. (same 10-K)
• margin_value_capture: High-margin proprietary biologics; value accrues in product sales and collaboration profit shares. FY2024 net income ~$4.4B on ~$14.2B revenue (~31% net margin). (same 10-K, financial statements)

• customer classes: Payers & Insurers, Health Systems & Providers, Pharma & Biotech (Sanofi/Bayer collaboration counterparties; distributors/specialty pharmacies as channel). (same 10-K, Business & segment/revenue notes)

Regeneron Pharmaceuticals, Inc. is a fully integrated biopharmaceutical company: it discovers, develops, manufactures, and commercializes biologic medicines in the United States, and in most ex-U.S. markets it operates through collaboration partners rather than building its own commercial infrastructure.

The company does not report multiple operating segments. Its Form 10-K for fiscal 2024 disaggregates revenue into four principal categories: (i) net product sales, (ii) Sanofi collaboration revenue, (iii) Bayer collaboration revenue, and (iv) other revenue. That disclosure is the foundation for the revenue-mix analysis below.

For fiscal 2024, Regeneron reported total revenues of $14,209.4 million, up from $13,117.2 million in fiscal 2023, per the audited consolidated statements of operations in the 10-K.

Source: Regeneron Form 10-K for fiscal year ended 2024-12-31, SEC EDGAR, accession 0000872589-25-000012, filed 2025-02-05, accessed 2026-04-11.

The company’s revenue is heavily concentrated in two economic franchises:

The key structural point is that Regeneron’s revenue is not a single product-line royalty model. U.S. product sales are recognized on a gross-to-net basis to distributors; collaboration revenues are mainly profit-share and reimbursement payments from Sanofi and Bayer, not simple royalty streams.

Regeneron’s largest product revenue stream is the EYLEA / EYLEA HD franchise in the United States. The company records U.S. net product sales for both the original 2 mg aflibercept formulation and the higher-dose 8 mg EYLEA HD formulation. Regeneron’s 10-K discloses that product revenues are concentrated in ophthalmology and that U.S. EYLEA sales face biosimilar and branded competition.

Source: Regeneron Form 10-K FY2024, Item 1 and Item 7, accession 0000872589-25-000012, filed 2025-02-05, accessed 2026-04-11.

The second-largest economic driver is Dupixent (dupilumab), which is marketed globally by Sanofi. Regeneron does not record Dupixent global net product sales as its own product revenue; instead, it records its share of the profits/losses from the Regeneron–Sanofi antibody collaboration as collaboration revenue. For fiscal 2024, Regeneron disclosed that global Dupixent net product sales recorded by Sanofi were approximately $14,146 million.

Source: Regeneron 8-K furnished with Q4/FY 2024 results, filed 2025-02-04, accession 0000872589-25-000004, accessed 2026-04-11.

The result is that Dupixent is economically more important to Regeneron than a simple look at Regeneron’s own product-sales line would suggest. It is a global blockbuster, but Regeneron’s income statement recognizes only its collaboration share.

Regeneron’s gross margin is structurally high because the company’s product revenue is biologic product with relatively low cost of goods sold, and because profit-share collaboration revenue generally carries no separate cost-of-product line. Based on the fiscal 2024 income statement, total revenues of $14,209.4 million and cost of revenues of approximately $1.16 billion imply a gross margin of roughly 92%.

Source: Regeneron Form 10-K FY2024 consolidated statements of operations; the cost-of-revenue dollar used for the implied margin calculation needs primary source validation, accession 0000872589-25-000012, filed 2025-02-05, accessed 2026-04-11.

Operating margin is lower because Regeneron remains a heavy R&D spender. The company reports substantial research and development expense, with SG&A also meaningful. The resulting operating margin is in the general range of the mid-40s to high-40s percent; the exact percentage should be recomputed from the 10-K because the precise R&D and SG&A lines were not re-verified to the XBRL instance in this session.

Regeneron monetizes its U.S. product franchise through buy-and-bill distribution: the company sells product to pharmaceutical distributors, which then sell to specialty pharmacies, retina clinics, physician offices, hospitals, and other healthcare providers. The provider purchases the medicine and is reimbursed by Medicare Part B, Medicaid, or commercial insurers. Therefore, Regeneron’s direct customers are not patients; they are distributors and healthcare providers. The ultimate payers are largely U.S. government payers and commercial insurers.

Source: Regeneron Form 10-K FY2024, Item 1, distribution and reimbursement discussion, accession 0000872589-25-000012, filed 2025-02-05, accessed 2026-04-11.

Regeneron’s 10-K customer-concentration disclosure identifies the large U.S. pharmaceutical distributors as its major customers. The named distributors are McKesson Corporation, AmerisourceBergen Corporation (now part of Cencora), and Cardinal Health, Inc.. The exact percentage of gross product revenues represented by these distributors in fiscal 2024 is a customer-concentration table item; the specific combined percentage I would state from memory is not cited here and is marked needs primary source validation.

Source: Regeneron Form 10-K FY2024, customer-concentration note, accession 0000872589-25-000012, filed 2025-02-05, accessed 2026-04-11.

Sanofi and Bayer are not customers in the conventional sense; they are collaboration counterparties. Sanofi is the commercializing party for Dupixent and certain other antibodies, and Bayer is the commercializing party for EYLEA/authored ex-U.S. aflibercept.

The most informative unit-economic calculation available from public filings is an implied Regeneron yield on global Dupixent sales. It is not a disclosed royalty rate; it is a derived all-in cash-flow yield from the Sanofi collaboration.

Formula

\[

\text{Implied Dupixent collaboration yield} =

\frac{\text{Regeneron Sanofi collaboration revenue}}{\text{Global Dupixent net product sales}}

\]

Using fiscal 2024 inputs:

\[

\text{Implied Dupixent collaboration yield} =

\frac{\$4,658.9\text{ million}}{\$14,146\text{ million}}

= 32.9\%

\]

The numerator, Regeneron Sanofi collaboration revenue of $4,658.9 million, is taken from the Sanofi collaboration note in Regeneron’s 10-K but is marked needs primary source validation because the exact allocation was not re-traced to a live XBRL instance in this session. The denominator, global Dupixent net sales of $14,146 million, is disclosed in the Q4/FY 2024 earnings 8-K.

Interpretation: a ~32.9% all-in yield does not mean Regeneron receives a 32.9% royalty on Dupixent net sales. Dupixent is governed by a profit/loss-sharing arrangement. The calculated yield is best understood as the cash-flow equivalent of Regeneron’s share of the Dupixent collaboration as a percentage of global recorded net sales.

Sensitivity

If Regeneron’s Sanofi collaboration revenue were 5% higher, the implied yield would rise to:

\[

\frac{\$4,891.8\text{ million}}{\$14,146\text{ million}} = 34.6\%

\]

If global Dupixent sales grew 15% but Regeneron’s collaboration revenue remained flat, the implied yield would decline to:

\[

\frac{\$4,658.9\text{ million}}{\$16,268\text{ million}} = 28.6\%

\]

This sensitivity matters because it shows that Regeneron’s Dupixent economics are sensitive to the profit share, not simply to top-line sales growth. If Dupixent is sold into markets with higher Sanofi commercialization costs or lower reimbursement, Regeneron’s yield can compress even as global sales rise.

Parameter table

This calculation is load-bearing for the view that Dupixent is a high-value collaboration asset but not a direct replacement for Regeneron’s own product-sales economics. Because the numerator is single-source and not independently cross-verified in a Sanofi filing, confidence in the exact 32.9% yield should be lowered; the structural conclusion—that Regeneron’s Dupixent economics are profit-share rather than simple royalties—is directly verifiable from the 10-K.

Regeneron’s customer architecture differs by product and geography.

For U.S. product sales, Regeneron sells to pharmaceutical distributors. The 10-K names the three principal distributors as McKesson Corporation, AmerisourceBergen Corporation/Cencora, and Cardinal Health, Inc. From those distributors, product reaches specialty pharmacies, retina clinics, ophthalmology practices, hospital outpatient departments, oncology clinics, and dermatology/respiratory practices.

Source: Regeneron Form 10-K FY2024, customer-concentration note, accession 0000872589-25-000012, filed 2025-02-05, accessed 2026-04-11.

The ultimate payers for U.S. product revenue are:

• Medicare Part B for physician-administered products such as EYLEA, EYLEA HD, and Libtayo. These are typically reimbursed under a buy-and-bill model.
• Commercial insurers for self-administered specialty products such as Dupixent and Praluent, whose distribution occurs through specialty pharmacy.
• Medicaid and other government payers for certain populations.

• Retina/ophthalmology practices and hospital eye departments are the primary purchasers for EYLEA and EYLEA HD. These are specialist physicians making treatment choices based on visual outcomes, injection burden, and reimbursement.
• Dermatologists, allergists, pulmonologists, and gastroenterologists are the prescribers for Dupixent across different indications.
• Oncologists and dermato-oncologists are the prescribers for Libtayo.
• Cardiologists, lipidologists, and primary-care physicians may prescribe Praluent.
• Payers and pharmacy benefit managers are gatekeepers whose formulary and prior-authorization decisions affect realized demand.

Outside the United States, Regeneron’s commercial presence is indirect. Sanofi commercializes Dupixent and certain other collaboration products; Bayer commercializes EYLEA and aflibercept-based products. Regeneron’s ex-U.S. revenue is therefore collaboration revenue, not product sales to local distributors.

Source: Regeneron Form 10-K FY2024, Item 1, collaboration agreements, accession 0000872589-25-000012, filed 2025-02-05, accessed 2026-04-11.

1. Franchise concentration (two-blockbuster dependency). Dupixent-linked revenue (Sanofi collaboration $2,174M) + EYLEA-linked revenue (EYLEA U.S. $1,008M + Bayer ex-US $276M) = $3,458M of $4,291M total = 80.6% of revenue from two antibody franchises. Regeneron is a two-engine platform with a diversification tail (Libtayo + pipeline), not a diversified pharma.

1. Dupixent profit-share capture rate. Dupixent global net sales (recorded by Sanofi) hit an all-time high $6.0B (+38% YoY); Regeneron's share of antibody commercialization profits was $2.033B (+59% YoY from $1.282B). Capture rate = $2.033B / $6.0B = ~34% — Regeneron keeps roughly one-third of every Dupixent dollar as profit share. This is the single most important number in the model: Dupixent profit share is compounding ~59% while the EYLEA 2 mg leg is −45%.

1. EYLEA 8 mg→2 mg transition (the managed LoE). EYLEA HD is now 59.1% of the U.S. franchise ($596M / $1,008M), up from 34.3% a year ago ($393M / $1,147M). The 8 mg high-dose formulation (longer dosing interval) is cannibalizing 2 mg ahead of biosimilar erosion — franchise is down −12% YoY but the mix is shifting to the still-protected 8 mg leg.

1. R&D intensity = "cost of the moat." Q2 R&D $1,631.6M = 38.0% of revenue; FY2026 GAAP R&D guidance raised to $6,500M–$6,635M. This ~38% of revenue is the price of sustaining the VelocImmune engine plus the clinical pipeline that must replace LoE. It is the moat's carrying cost.

1. Buyback leverage. GAAP net income fell −7% YoY ($1,296.9M vs $1,391.6M) yet GAAP diluted EPS grew +11% (~$12.01) — implying a ~15–18% share-count reduction. Regeneron is using its ~$8.0B cash + marketable-securities pile to buy back shares while the two franchises still generate 30% operating margins.

1. Operating leverage check. Operating income $1,293.5M = 30.1% operating margin (Q2 2026), up ~70 bps YoY from 29.4% ($1,079.5M / $3,675.6M).

• technical_scarcity: 7/10 — approved-franchise + indication-stack + safety-database barrier (Dupixent 6+ indications, EYLEA HD protected); fianlimab failure confirms the platform does not guarantee clinical wins (scarcity is franchise-high, platform-moderate).
• economic_capture: 8/10 — 30.1% operating margin, ~34% Dupixent profit-share capture ($2.033B of $6.0B), ~$8.0B cash, non-GAAP EPS +11%; capture intact even as GAAP NI −7% (LoE + R&D ramp absorbing Dupixent upside).
• time_to_monetize: 7/10 — already monetizing (Dupixent +38%, Libtayo +30%, EYLEA HD +52%); near catalysts = Sanofi-balance Q3 profit step-up + cemdisiran Nov 2026 PDUFA + Lynozyfic launch, offset by fianlimab catalyst removal.

Hypothesis verdict: INTACT (reconciled from DB NEEDS_MORE_DATA; the 08-16 STRENGTHENED predates the fianlimab-1L-melanoma flag). The two-anchor franchise is intact and compounding (Dupixent +59% profit share, EYLEA HD +52%, Libtayo +30%), but net product sales are +1% (franchise rotation, not net growth) and the replacement pipeline just lost a key oncology asset — INTACT, not STRENGTHENED.

• SEC 8-K EX-99.1 (Q2 2026 earnings + pipeline update, filed 2026-07-30): sec.gov
• SEC 10-Q Q2 2026 (regn-20260630.htm): sec.gov
• SEC companyfacts CIK 0000872589: data.sec.gov